SCM
CRL icon

Soleus Capital Management’s Charles River Laboratories CRL Stock Holding History

Soleus Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-96,064
Closed -$18.8M – 83
2023
Q3 		$18.8M Sell
96,064
-113,432
-54% -$23.3M 1.74% 19
2023
Q2 		$44M Buy
209,496
+53,400
+34% +$10.6M 4.9% 3
2023
Q1 		$31.5M Buy
156,096
+54,246
+53% +$12.3M 3.26% 5
2022
Q4 		$22.2M Sell
101,850
-27,250
-21% -$5.95M 3.18% 8
2022
Q3 		$25.4M Buy
+129,100
New +$27.9M 3.45% 9

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Soleus Capital Management's CRL Position: Q4 2023 in Review

Soleus Capital Management sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 96,064 shares — an estimated $18.8M sold.

Soleus Capital Management first reported a position in CRL in Q3 2022 and held it in 5 quarters. The position peaked at $44M in Q2 2023. 633 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • Soleus Capital Management reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 96,064 Charles River Laboratories shares in Q4 2023, an estimated $18.8M.
  • Soleus Capital Management first reported a position in Charles River Laboratories in Q3 2022 and held it in 5 quarters.
  • Soleus Capital Management's Charles River Laboratories position peaked at $44M in Q2 2023.
  • 633 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.